Bank of America Corp DE Has $2.14 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Bank of America Corp DE boosted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 49.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 384,880 shares of the company's stock after purchasing an additional 127,885 shares during the quarter. Bank of America Corp DE owned about 0.83% of 4D Molecular Therapeutics worth $2,144,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after buying an additional 92,791 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in 4D Molecular Therapeutics by 159.5% in the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after purchasing an additional 504,086 shares during the period. Norges Bank acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $2,790,000. Northern Trust Corp grew its position in shares of 4D Molecular Therapeutics by 2.3% during the 4th quarter. Northern Trust Corp now owns 440,665 shares of the company's stock worth $2,455,000 after purchasing an additional 9,982 shares in the last quarter. Finally, Decheng Capital LLC increased its holdings in shares of 4D Molecular Therapeutics by 0.5% during the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock worth $2,228,000 after purchasing an additional 2,165 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

FDMT has been the subject of several recent research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 24th. Chardan Capital reduced their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, May 9th. The Goldman Sachs Group dropped their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Stock Up 2.1%

Shares of NASDAQ:FDMT traded up $0.08 during trading on Thursday, hitting $3.91. 102,579 shares of the company were exchanged, compared to its average volume of 702,014. The business's 50 day moving average is $3.24 and its 200-day moving average is $4.71. The company has a market capitalization of $181.13 million, a P/E ratio of -1.37 and a beta of 2.84. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). As a group, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.